熱門資訊> 正文
X4 Pharmaceuticals将裁员50%
2025-09-17 19:33
- X4 Pharmaceuticals (NASDAQ:XFOR) has announced a restructuring program to align resources with its long-term strategy to complete the Phase 3 4WARD trial for chronic neutropenia.
- The plan includes cutting 50% of its workforce, expected to save about $13M annually. As part of the workforce reduction, chief legal & compliance officer Natasha Thoren; chief operating officer Mary DiBiase; and chief commercial officer Mark Baldry will be exiting the firm. John Volpone has been appointed chief operating officer, in addition to his current role as president.
- Chief medical officer Christophe Arbet‑Engels is resigning for personal reasons and will remain available to support transition activities. Adam Craig, executive chairman, will oversee clinical development.
- XFOR +2.49% premarket to $3.29
- Source: Press Release
More on X4 Pharmaceuticals
- Seeking Alpha’s Quant Rating on X4 Pharmaceuticals
- Historical earnings data for X4 Pharmaceuticals
- Financial information for X4 Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
